TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04514614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
Study: NCT00302393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS methylphenidate hydrochloride
Description: Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate hydrochloride
Description: Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
Study: NCT04492904

Intervention type: OTHER
Intervention: Home-use Test and Follow-up Questionnaire
Description: Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.

Intervention type: OTHER
Intervention: Home-use Test and Follow-up Questionnaire
Description: Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
Study: NCT04695509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3
Description: Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)
Description: Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
Study: NCT04614818

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research

Intervention type: OTHER
Intervention: Non-intervention research
Description: Non-intervention research
Study: NCT00441688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI265235
Study: NCT00855439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
Study: NCT04297943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthosis fabrication
Description: see summary

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthosis fabrication
Description: see summary

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal Sensor Monitoring of Orthosis Use
Description: see summary

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal Sensor Monitoring of Orthosis Use
Description: see summary

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4D CT Scan
Description: see summary

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4D CT Scan
Description: see summary
Study: NCT03731663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to pictures of appetizing food (known as Foodporn)
Description: - Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exposure to neutral pictures
Description: Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
Study: NCT04604925

Intervention type: BEHAVIORAL
Intervention: Remote patient monitoring for hypertension
Description: Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
Study: NCT04078750

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Tailored medication adherence plan
Description: Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored medication adherence plan
Description: Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
Study: NCT04193748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical pomegranate seeds and peel extracts
Description: Topical pomegranate seeds and peel extracts in the form of gel
Study: NCT03880266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium cloth, 2.4%
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium cloth, 2.4%
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium cloth, 2.4%
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth
Study: NCT02889848

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Comparison of maximum marketed dose and multiple doses EN3835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Comparison of maximum marketed dose and multiple doses EN3835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Comparison of maximum marketed dose and multiple doses EN3835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Comparison of maximum marketed dose and multiple doses EN3835
Study: NCT04011345

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic Acid Supplement
Description: 1 milligram folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic Acid Supplement
Description: 1 milligram folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT00927303

Intervention type: DEVICE
Intervention: Cirrus-Spectralis
Description: 512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter

Intervention type: DEVICE
Intervention: Cirrus-Spectralis
Description: 512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter

Intervention type: DEVICE
Intervention: Cirrus-Spectralis
Description: 512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter

Intervention type: DEVICE
Intervention: Cirrus-Spectralis
Description: 512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter

Intervention type: DEVICE
Intervention: Spectralis-Cirrus
Description: retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter

Intervention type: DEVICE
Intervention: Spectralis-Cirrus
Description: retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter

Intervention type: DEVICE
Intervention: Spectralis-Cirrus
Description: retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter

Intervention type: DEVICE
Intervention: Spectralis-Cirrus
Description: retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
Study: NCT03609983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily weighing with daily feedback on weight
Description: Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly weighing with weekly feedback on weight
Description: Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories.
Study: NCT03462654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iLiFE
Description: In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gLiFE
Description: The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
Study: NCT02253498

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep brain stimulation (DBS)
Study: NCT01859000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy
Description: MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.

Intervention type: OTHER
Group type: OTHER
Intervention: Group CBT
Description: Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
Study: NCT00460798

Intervention type: OTHER
Intervention: Sutent: observational study
Description: SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Study: NCT03290820

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
Study: NCT00488215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
Study: NCT03844321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: 8 sessions of online mindfulness-based cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness
Description: 3 sessions of online mindfulness therapy
Study: NCT00729690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
Study: NCT05140213

Intervention type: DEVICE
Intervention: Anti-infectious prescription support tool
Description: implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.

Intervention type: DEVICE
Intervention: Anti-infectious prescription support tool
Description: implementation of a pocket notebook with current anti-infectious recommendations in the emergency department Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief.
Study: NCT03290820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy
Description: Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Daily aspirin of 75mg, from the starting date of radiotherapy.
Study: NCT03135834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis group A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: N meningitidis group A, B, C, W, and Y vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086
Description: Bivalent recombinant lipoprotein 2086 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: meningococcal group A, C, W-135, and Y conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: meningococcal group A, C, W-135, and Y conjugate vaccine
Study: NCT03073330

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GDM screening with 75 g 2 hour GTT
Description: Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GDM screening with two step approach
Description: 1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
Study: NCT02050685

Intervention type: OTHER
Intervention: All patients incoming in the sleep study centre for a PSG
Description: All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
Study: NCT02071797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Therapeutic Hypothermia
Description: Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Induced Therapeutic Hypothermia
Description: Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
Study: NCT00793663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous use, 4 mg, single shot

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Intravenous use; single shot

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Intravenous use; 4 mg; single shot

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Intravenous use; single shot